מכפיל EV/EBITDA: Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals (ACXP) is developing advanced selective antibiotics for the treatment of complex gastrointestinal infections, leveraging a robust R&D foundation. This EV/EBITDA chart, which currently stands at 0.00, complements data regarding the implementation of Phase II trials for its highly specialized drugs. Meanwhile, the company's financial position is driven by investment rounds, as regular operating revenues are temporarily absent.

This multiple serves as a key filter during asset stress testing, allowing for the determination of a business's fair value adjusted for net debt. The metric compares the total enterprise value with its operating profit before depreciation and taxes, measuring the investment payback period. Analyzing the EV/EBITDA ratio for Acurx Pharmaceuticals (ACXP) across a financial timeline is complicated by a lack of revenue due to its clinical trial stage, rendering the indicator dependent on FDA approval prospects.